Brand: ProteoGenix

RBD Domain

PX-COV-P046-50
5 publications
Quality Chart

Note:: For research use only. Not suitable for human use.

€250.00

50ug + 250 loyalty points

Spike protein fragment

size size

50ug €250.00
100ug €330.00

First Name This field is required. Last Name This field is required. Email This field is required. Company This field is required. Country This field is required. State This field is required.

In Stock
Free shipping in EU on orders > €500
Wide range of unique reagents
Fast worldwide delivery

SDS-PAGE for RBD Domain Recombinant proteins

Anti-RBD-1 (Etesevimab) antibody binds to RBD Domain in indirect ELISA Assay

Datasheet

RBD Domain

Product name	RBD Domain
Origin species	SARS-COV2
Expression system	Eukaryotic expression
Raw Antigen Sequence	MN908947
Molecular weight	23,6kDa
Purity estimated	95%
Buffer	PBS, pH 7,5
Form	liquid
Delivery condition	Dry Ice
Storage condition	4°C for short term; -20°c or -80°C for long term
Brand	ProteoGenix
Host species	Mammalian cells
Fragment Type	Spike protein fragment
Aliases /Synonyms	Receptor binding domain (RBD) in Spike protein S1
Reference	PX-COV-P046
Note	For research use only
Molecular Constructor	Spike protein fragment

Product name	RBD Domain
Origin species	SARS-COV2
Expression system	Eukaryotic expression
Raw Antigen Sequence	MN908947
Molecular weight	23,6kDa
Purity estimated	95%
Buffer	PBS, pH 7,5
Form	liquid
Delivery condition	Dry Ice
Storage condition	4°C for short term; -20°c or -80°C for long term
Brand	ProteoGenix
Host species	Mammalian cells
Fragment Type	Spike protein fragment
Aliases /Synonyms	Receptor binding domain (RBD) in Spike protein S1
Reference	PX-COV-P046
Note	For research use only
Molecular Constructor	Spike protein fragment

General information on RBD Domain

RBD is a receptor-binding domain located on the spike protein of coronavirus (CoV). The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease 2019 (COVID-19) is a CoV species. COVID virus contains four structural proteins; spike (S), nucleocapsid (N), envelope (E) and membrane (M) proteins. CoV spike protein is responsible for viral attachment, fusion and entry. Spike protein consists of two domains, namely S1 and S2, which are responsible for the binding step. S1 domain is involved in host cell receptor recognition and binding whereas S1 domain contain the putative fusion peptide as well as heptad repeat HR1 and HR2. S1 contains RBD protein domain.
RBD domain is believed to have a pivotal role in spike protein-induced viral attachment, fusion and entry. RBD domain binds strongly to angiotensin-converting enzyme 2 (ACE2) receptors. These receptors are located in the cells of most organs including lungs, kidneys, heart, arteries and cerebral cortex. Once the spike protein binds to ACE2 receptors, the viral enters the cell via endocytosis and is soon after transferred in the endosome of the target cell. SARS-CoV-2 RBD shows high binding affinity to ACE2 receptors with human and bat origin. SARS-CoV-2 RBD binds strongly to 293T-expressed in bat cell ACE2 receptors with a similar intensity to that of its binding to 293T-expressed in human cell ACE2 receptors. Furthermore, the binding is dose dependent. The strong binding of SARS-CoV RBD to either bat ACE2 or human ACE2 may partially explain why SARS-CoV-2 is more transmissible than other CoV species.
Polyclonal antibodies that specifically targeted RBD domain of SARS-CoV spike protein and cross-reacted with SARS-CoV-2 RBD protein were able to inhibit SARS-CoV-2 entry into target human cells that expressed ACE2 receptor. Furthermore, polyclonal antibodies cross-neutralized SARS-CoV-2 pseudovirus infection. This suggest a SARS-CoV RBD-based vaccine as a potential target for prevention of infection by SARS-CoV-2 and SARS-CoV.

Datasheet

SDS-PAGE for RBD Domain Recombinant proteins

RBD Domain Recombinant proteins, on SDS-PAGE under reducing. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Anti-RBD-1 (Etesevimab) antibody binds to RBD Domain in indirect ELISA Assay

Immobilized RBD Domain (cat. No.PX-COV-P046) at 0.5µg/mL (100µL/well) can bind to Anti-RBD-1 (Etesevimab) antibody (cat. No.PTXCOV-A549) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450

Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb binds to RBD Domain in Indirect ELISA Assay

Immobilized RBD Domain (cat. No.PX-COV-P046) at 0.5µg/mL (100µL/well) can bind to Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb (cat. No.PX-TA1637) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450

Winklmeier, S. et al. Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. medRxiv 2021.05.15.21257210. doi: https://doi.org/10.1101/2021.05.15.21257210
Pannus, P. et al. Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial. medRxiv 2022.03.25.22272599 https://doi.org/10.1371/journal.pgph.0001308
Winklmeier S, Rübsamen H, Özdemir C, Wratil PR, Lupoli G, Stern M, Schneider C, Eisenhut K, Ho S, Wong HK, Taskin D, Petry M, Weigand M, Eichhorn P, Foesel BU, Mader S, Keppler OT, Kümpfel T and Meinl E (2024) Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva. Front. Immunol. 15:1330864. doi: https://doi.org/10.3389/fimmu.2024.1330864
Hubert Bernauer, Anja Schlör, Josef Maier, Norbert Bannert, Katja Hanack, Daniel Ivanusic, tANCHOR fast and cost-effective cell-based immunization approach with focus on the receptor-binding domain of SARS-CoV-2, Biology Methods and Protocols, Volume 8, Issue 1, 2023, bpad030, https://doi.org/10.1093/biomethods/bpad030
Nicolas Gemander, Delphine Kemlin, Stéphanie Depickère, Natasha S. Kelkar, Pieter Pannus, Shilpee Sharma, Alexandra Waegemans, Véronique Olislagers, Daphnée Georges, Emilie Dhondt, Margarida Braga, Leo Heyndrickx, Johan Michiels, Anaïs Thiriard, Anne Lemy, Marylène Vandevenne, Maria E. Goossens, André Matagne, Isabelle Desombere, Kevin K. Ariën, Margaret E. Ackerman, Alain Le Moine, Arnaud Marchant, Hybrid Immunity Overcomes Defective Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients, Kidney International Reports, 2023, ISSN 2468-0249, https://doi.org/10.1016/j.ekir.2023.12.008.